STOCK TITAN

Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

RHYTHM PHARMACEUTICALS director Jean Christophe reported equity awards and an RSU conversion into common stock. He received 2,324 restricted stock units, each representing one share of common stock, which fully vest upon the earlier of June 24, 2027 or the day before the 2027 annual meeting, subject to continued service.

He also received stock options for 3,691 shares of common stock at an exercise price of $107.55 per share, vesting on the same schedule and expiring on June 23, 2036. In addition, 4,712 previously granted restricted stock units were exercised and converted into 4,712 shares of common stock, leaving no remaining units from that grant. Following these transactions, he holds 11,712 shares of common stock directly.

Positive

  • None.

Negative

  • None.
Insider JEAN CHRISTOPHE
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,691 $0.00 --
Grant/Award Restricted Stock Units 2,324 $0.00 --
Exercise Restricted Stock Units 4,712 $0.00 --
Exercise Common Stock 4,712 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,691 shares (Direct, null); Restricted Stock Units — 2,324 shares (Direct, null); Common Stock — 11,712 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units are fully vested. The restricted stock units have no expiration date. The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
RSU grant 2,324 units Restricted stock units granted to director, each for one common share
Option grant size 3,691 shares Stock options granted for common stock
Option exercise price $107.55 per share Conversion or exercise price of stock options
Option expiration June 23, 2036 Expiration date of stock options granted
RSUs converted 4,712 units Restricted stock units exercised into common stock
Common shares after 11,712 shares Common stock directly held after transactions
RSU grant vesting June 24, 2027 / pre-2027 meeting Earlier of date or day before 2027 annual meeting, subject to service
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (right to buy) financial
"The options fully vest upon the earlier of June 24, 2027 or before the 2027 meeting"
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vest financial
"The options fully vest upon the earlier of June 24, 2027 or the day"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
JEAN CHRISTOPHE

(Last)(First)(Middle)
C/O RHYTHM PHARMACEUTICALS, INC.
222 BERKELEY STREET, 12TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/23/2026M4,712A(1)11,712D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)06/23/2026M4,712 (2) (2)Common Stock4,712$00D
Stock Option (right to buy)$107.5506/24/2026A3,691 (3)06/23/2036Common Stock3,691$03,691D
Restricted Stock Units(1)06/24/2026A2,324 (4) (4)Common Stock2,324$02,324D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
2. The restricted stock units are fully vested. The restricted stock units have no expiration date.
3. The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.
4. The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
/s/ Stephen Vander Stoep, attorney-in-fact for Christophe Jean06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Rhythm Pharmaceuticals (RYTM) director Jean Christophe receive?

Jean Christophe received 2,324 restricted stock units and stock options for 3,691 shares at $107.55 per share. Both awards vest by June 24, 2027 or the day before the 2027 annual meeting, subject to his continued service on the board.

How many Rhythm Pharmaceuticals (RYTM) shares does Jean Christophe hold after this Form 4?

After these transactions, Jean Christophe directly holds 11,712 shares of Rhythm Pharmaceuticals common stock. This reflects the conversion of 4,712 previously granted restricted stock units into common shares, with no open-market sales reported in this filing.

What happened to the 4,712 restricted stock units in Jean Christophe’s Rhythm (RYTM) filing?

4,712 restricted stock units were exercised and converted into 4,712 shares of Rhythm common stock. This transaction is coded as an exercise of a derivative security, leaving no remaining units from that specific RSU grant outstanding after the conversion.

When do Jean Christophe’s new Rhythm (RYTM) RSUs and options vest?

Both the 2,324 restricted stock units and the 3,691 stock options vest upon the earlier of June 24, 2027 or the day immediately prior to Rhythm’s 2027 annual shareholder meeting, provided Jean Christophe continues serving as a director through the applicable vesting date.

What is the exercise price and expiration date of Jean Christophe’s Rhythm (RYTM) options?

Jean Christophe’s newly granted stock options cover 3,691 shares of Rhythm common stock at an exercise price of $107.55 per share. These options expire on June 23, 2036, giving a long-dated window once vesting conditions tied to board service are met.